Research programme: cyplasin glycoprotein - Bioxen

Drug Profile

Research programme: cyplasin glycoprotein - Bioxen

Alternative Names: Cyplasin; Cyplasin-SC

Latest Information Update: 04 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyplasin Biomedical
  • Developer Bioxen
  • Class Glycoproteins; Recombinant proteins
  • Mechanism of Action Actin modulators; Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 13 Feb 2009 Cysplasin glycoprotein licensed to Bioxen worldwide
  • 11 Jan 2008 Cyplasin Biomedical completes equity financing totalling $US1.1 million
  • 12 Oct 2007 Preclinical data added to the adverse events and Cancer pharmacodynamics sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top